Matt Hewitt

Stock Analyst at Craig-Hallum

(0.69)
# 2350
Out of 5,347 analysts
54
Total ratings
46.15%
Success rate
-0.74%
Average return
19 Stocks
Name Action PT Current % Upside Ratings Updated
CSBR Champions Oncology
Maintains: Strong Buy
8 12
5.94 102.02% 4 Mar 12, 2025
BLFS BioLife Solns
Maintains: Strong Buy
30 32
21.87 46.32% 4 Nov 13, 2024
OMCL Omnicell
Maintains: Strong Buy
45 64
30.37 110.73% 5 Oct 31, 2024
LGND Ligand Pharmaceutica...
Maintains: Strong Buy
135 140
102.05 37.19% 3 Jul 9, 2024
SLP Simulations Plus
Reiterates: Buy
56 56
31.82 75.99% 7 Jul 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
25 10
2.6 284.62% 3 May 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
35 30
21.61 38.82% 3 May 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 2 Jan 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
23
n/a n/a 1 Jan 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
22 16
n/a n/a 4 Dec 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
7
2.39 192.89% 1 Nov 29, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
207 200
118.06 69.41% 3 Aug 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
10
1.27 687.4% 1 Apr 13, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
5 2
n/a n/a 2 Mar 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
3 2
n/a n/a 1 May 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
67 30
6.92 333.53% 5 Apr 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
400
1.27 31396.06% 1 Jan 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
21 30
n/a n/a 3 Jul 28, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
11
n/a n/a 1 Jul 24, 2017